Athira Pharma (NASDAQ:LONA) Raised to Hold at Wall Street Zen

Athira Pharma (NASDAQ:LONA) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings began coverage on Athira Pharma in a research report on Wednesday. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Athira Pharma Price Performance

Shares of LONA stock opened at $4.34 on Friday. The company has a market capitalization of $17.10 million, a P/E ratio of -0.45 and a beta of 2.73. Athira Pharma has a 1 year low of $2.20 and a 1 year high of $8.36.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.